Clinical Trial Update: Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating daily Truvada for HIV pre-exposure prophylaxis (PrEP) in adolescents, focusing on acceptability, safety, and use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2023-07-03